Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease

Endocrine Practice

Volumn 17, Issue 3, 2011, Pages 430-440

  Hershon, Kenneth S ^a  

^a N Shore Diabet and Endocr Assoc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; NATEGLINIDE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; VALSARTAN;

BLOOD FLOW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; COMORBIDITY; DISEASE ASSOCIATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; MEDLINE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; MODELS, BIOLOGICAL; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; TETRAZOLES; VALINE;

EID: 79959679349     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP10106.RA     Document Type: Review

References (59)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007 (Erratum in Diabetes Care. 2008; 31:1271). Diabetes Care. 2008;31:596-615.
2. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care. 2009;32(Suppl 1):S13-S61.
3. Centers for Disease Control and Prevention. Estimates of diagnosed diabetes now available for all U.S. counties. 2008. Available at: Http://www.cdc.gov/media/pressrel/2008/r080624.htm. Accessed April 15, 2009.
4. Santaguida PL, Balion C, Hunt D, et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summary). 2005;128:1-11.
5. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs. 2004; 64:2537-2565. (Pubitemid 39591650)
6. Leung PS, de Gasparo M. Involvement of the pancreatic renin-angiotensin system in insulin resistance and the metabolic syndrome. J Cardiometab Syndr. 2006;1:197-203.
7. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev. 1996;76:425-536. (Pubitemid 26163714)
8. Handa RK, Ferrario CM, Strandhoy JW. Renal actions of angiotensin-(1-7): In vivo and in vitro studies. Am J Physiol. 1996;270:F141-F147.
9. Tallant EA, Diz DI, Ferrario CM. State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension. 1999;34:950-957. (Pubitemid 29501329)
10. Blendea MC, Jacobs D, Stump CS, et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab. 2005;288:E353-E359. (Pubitemid 40110643)
11. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin- aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005;16:120-126. (Pubitemid 40432462)
12. Leiter LA, Lewanczuk RZ. Of the renin-angiotensin system and reactive oxygen species type 2 diabetes and angiotensin II inhibition. Am J Hypertens. 2005;18:121-128. (Pubitemid 40187358)
13. Shah S, Iqbal M, Karam J, Salifu M, McFarlane SI. Oxidative stress, glucose metabolism, and the prevention of type 2 diabetes: Pathophysiological insights. Antioxid Redox Signal. 2007;9:911-929. (Pubitemid 46919593)
14. Shiuchi T, Iwai M, Li HS, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension. 2004;43: 1003-1010. (Pubitemid 38579905)
15. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: Implications for diabetes. Mol Cell Endocrinol. 2009;302:128-139.
16. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 2000;35:1270-1277. (Pubitemid 30413663)
17. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes. 2002;51:1699-1707. (Pubitemid 34564280)
18. Lenz O, Fornoni A. Renin-angiotensin system blockade and diabetes: Moving the adipose organ from the periphery to the center. Kidney Int. 2008;74:851-853.
19. Saint-Marc P, Kozak LP, Ailhaud G, Darimont C, Negrel R. Angiotensin II as a trophic factor of white adipose tissue: Stimulation of adipose cell formation. Endocrinology. 2001;142:487-492. (Pubitemid 32183711)
20. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: Relationship to obesity and hypertension. J Hypertens. 2002;20:965-973. (Pubitemid 34913678)
21. Yilmaz MI, Sonmez A, Caglar K, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton ). 2007;12:147-153. (Pubitemid 46426854)
22. Anderson EA, Mark AL. The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension [Erratum in: Hypertension. 1993;21:745]. Hypertension. 1993;21:136-141. (Pubitemid 23035065)
23. Wei Y, Whaley-Connell AT, Chen K, et al. NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension. 2007;50:384-391. (Pubitemid 47205789)
24. Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM, Stump CS. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kB activation via NADPH oxidase. Am J Physiol Endocrinol Metab. 2008;294:E345-E351. (Pubitemid 351231460)
25. Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med. 2007;46:1331-1336. (Pubitemid 47455754)
26. Jordan J, Engeli S, Boschmann M, et al. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. J Hypertens. 2005;23:2313-2318. (Pubitemid 41666762)
27. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563-1574. (Pubitemid 36994137)
28. Paolisso G, Tagliamonte MR, Gambardella A, et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens. 1997;11:307-312. (Pubitemid 27299765)
29. Top C, Cingözbay BY, Terekeci H, Küçükardali Y, Onde ME, Danaci M. The effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res. 2002;30:15-20. (Pubitemid 34618717)
30. Leung PS. The physiology of a local renin-angiotensin system in the pancreas. J Physiol. 2007;580:31-37. (Pubitemid 46470642)
31. Cheng Q, Law PK, de Gasparo M, Leung PS. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2- cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl] -L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J Pharmacol Exp Ther. 2008;327: 683-691.
32. Lupi R, Del Guerra S, Bugliani M, et al. The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J Endocrinol. 2006;154:355-361.
33. Nakayama M, Inoguchi T, Sonta T, et al. Increased expression of NAD(P)H oxidase in islets of animal models of type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochem Biophys Res Commun. 2005;332:927-933. (Pubitemid 40798176)
34. Siragy HM. Improving vascular function in hypertension: Potential benefits of combination therapy with amlodipine and renin-angiotensin- aldosterone system blockers. J Hypertens. 2010;28:2-8.
35. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-126. (Pubitemid 46058619)
36. Yusuf S, Gerstein H, Hoogwerf B, et al; HOPE Study Investigators. Ramipril and the development of diabetes. JAMA. 2001;286:1882-1885. (Pubitemid 33010241)
37. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [Errata in: N Engl J Med. 2000;342:748 and N Engl J Med. 2000;342:1376]. N Engl J Med. 2000;342:145-153.
38. DREAM Trial Investigators, Bosch J, Yusuf S, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551-1562. (Pubitemid 44550032)
39. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: Insight from the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 2003;107:1291-1296. (Pubitemid 36314413)
40. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616. (Pubitemid 29087980)
41. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
42. Lindholm LH, Ibsen H, Borch-Johnsen K, et al; LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002;20:1879-1886.
43. Yusuf S, Ostergren JB, Gerstein HC, et al; Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation. 2005;112:48-53. (Pubitemid 40962568)
44. Lithell H, Hansson L, Skoog I, et al; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886. (Pubitemid 36677151)
45. Kjeldsen SE, Julius S, Mancia G, et al; VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: Tthe VALUE trial. J Hypertens. 2006;24: 1405-1412. (Pubitemid 43948341)
46. The NAVIGATOR Study Group, McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events [Erratum in: N Engl J Med. 2010;362:1748]. N Engl J Med. 2010;362:1477-1490.
47. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
48. Fox KM; European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788. (Pubitemid 37093919)
49. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592. (Pubitemid 36204952)
50. Califf RM, Boolell M, Haffner SM, et al; NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 2008;156:623-632.
51. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization. Department of Noncommunicable Disease Surveillance, 1999.
52. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787-794. (Pubitemid 29536364)
53. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675. (Pubitemid 33126822)
54. Pfeffer MA, McMurray JJ, Velazquez EJ, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906. (Pubitemid 37409706)
55. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet. 2002;359: 2072-2077. (Pubitemid 34680970)
56. Stojiljkovic L, Behnia R. Role of renin angiotensin system inhibitors in cardiovascular and renal protection: A lesson from clinical trials. Curr Pharm Des. 2007;13:1335-1345. (Pubitemid 46746371)
57. Siragy HM. Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Adv Ther. 2010;27: 257-284.
58. Bommer WJ. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: Part 2. Prev Cardiol. 2008;11:215-222.
59. Bommer WJ. Use of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy to reduce cardiovascular events in high-risk patients: Part 1. Prev Cardiol. 2008;11:148-154.